Literature DB >> 1510447

Molecular basis of the non-beta-lactamase-mediated resistance to beta-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada.

N Clairoux1, M Picard, A Brochu, N Rousseau, P Gourde, D Beauchamp, T R Parr, M G Bergeron, F Malouin.   

Abstract

A study recently conducted across Canada showed that 64 of 2,503 clinical isolates of Haemophilus influenzae were resistant to beta-lactams without production of a beta-lactamase (L. D. Tremblay, J. L'Ecuyer, P. Provencher, M. G. Bergeron, and Canadian Study Group, Can. Med. Assoc. J. 143:895-900, 1990). The beta-lactamase-negative strains formed three distinct groups, with ampicillin MICs of 0.5 to 1, 2 to 4, and greater than or equal to 8 micrograms/ml for groups I, II, and III, respectively. We have investigated the mechanisms of resistance for eight strains originating from different infections and geographic areas. These strains were representative of groups I to III. Five strains were nontypeable, two were type B, and one was non-B. Chromosomal DNA extracted from each strain was used to transform the laboratory strain Rd. Transformants were selected on beta-lactam-containing plates and showed the same level of resistance to ampicillin as the donor strains. Differences in outer membrane proteins, porins, and lipopolysaccharide profiles on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) did not change with resistance. Functional analyses of purified porins in artificial lipid bilayer experiments did not explain resistance. Peptidoglycan synthesis was measured by incorporation of [14C]alanine into trichloroacetic acid-insoluble cell wall material in the presence of chloramphenicol. The growth rate and the rate of peptidoglycan synthesis observed for the transformants of the isogenic set did not correlate with resistance. Whole-cell labeling with 125I-penicillin revealed modifications in penicillin-binding proteins (PBPs) among the transformants. In particular, PBPs 3A and 3B (65 and 63 kDa, respectively) showed a decrease in affinity for beta-lactams in all transformants (groups I, II, and III) and correlated with an increased MIC except in the transformant of group III, which showed higher levels of resistance. Partial purification and proteolytic digestion of 125I-penicillin-labeled PBP 3B led to two types of CnBr peptide profiles on SDS-PAGE, the profiles of the transformed strains from groups I and II being different from those of the control group and group III. Finally, electron microscopy revealed a distinct cell filamentation for the group III transformants. These data clearly indicate that changes in PBPs are a common mechanism that results in a significant level of non-beta-lactamase-mediated beta-lactam resistance in H. influenzae despite serotype, origin of isolation, or geographic distribution.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1510447      PMCID: PMC191612          DOI: 10.1128/AAC.36.7.1504

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.

Authors:  S Chamberland; F Malouin; H R Rabin; T Schollaardt; T R Parr; L E Bryan
Journal:  J Antimicrob Chemother       Date:  1990-06       Impact factor: 5.790

2.  Biological characterization of a new radioactive labeling reagent for bacterial penicillin-binding proteins.

Authors:  D A Preston; C Y Wu; L C Blaszczak; D E Seitz; N G Halligan
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

3.  Rapid microprocedure for isolating detergent-insoluble outer membrane proteins from Haemophilus species.

Authors:  G M Carlone; M L Thomas; H S Rumschlag; F O Sottnek
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

4.  Defined nongrowth media for stage II development of competence in Haemophilus influenzae.

Authors:  R M Herriott; E M Meyer; M Vogt
Journal:  J Bacteriol       Date:  1970-02       Impact factor: 3.490

Review 5.  The biology of natural transformation.

Authors:  G J Stewart; C A Carlson
Journal:  Annu Rev Microbiol       Date:  1986       Impact factor: 15.500

6.  Influence of growth media on Escherichia coli cell composition and ceftazidime susceptibility.

Authors:  F Malouin; S Chamberland; N Brochu; T R Parr
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

7.  Maturation of the head of bacteriophage T4. I. DNA packaging events.

Authors:  U K Laemmli; M Favre
Journal:  J Mol Biol       Date:  1973-11-15       Impact factor: 5.469

8.  Properties of the penicillin-binding proteins of Escherichia coli K12,.

Authors:  B G Spratt
Journal:  Eur J Biochem       Date:  1977-01

9.  Cloning and expression of genes responsible for altered penicillin-binding proteins 3a and 3b in Haemophilus influenzae.

Authors:  F Malouin; A B Schryvers; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

Review 10.  Nontypable Haemophilus influenzae: a review of clinical aspects, surface antigens, and the human immune response to infection.

Authors:  T F Murphy; M A Apicella
Journal:  Rev Infect Dis       Date:  1987 Jan-Feb
View more
  25 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae.

Authors:  K Ubukata; Y Shibasaki; K Yamamoto; N Chiba; K Hasegawa; Y Takeuchi; K Sunakawa; M Inoue; M Konno
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Genetic and molecular characterization of beta-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin.

Authors:  Frank S Kaczmarek; Thomas D Gootz; Fadia Dib-Hajj; Wenchi Shang; Shawn Hallowell; Melissa Cronan
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

4.  Haemophilus influenzae: then and now.

Authors:  J Z Jordens; M P Slack
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

5.  Epidemiology and evolution of antibiotic resistance of Haemophilus influenzae in children 5 years of age or less in France, 2001-2008: a retrospective database analysis.

Authors:  H Dabernat; C Delmas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-04-27       Impact factor: 3.267

6.  Amoxicillin treatment of experimental acute otitis media caused by Haemophilus influenzae with non-beta-lactamase-mediated resistance to beta-lactams: aspects of virulence and treatment.

Authors:  A Melhus; H Janson; E Westman; A Hermansson; A Forsgren; K Prellner
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

7.  Heterogeneity of Actinobacillus actinomycetemcomitans strains in various human infections and relationships between serotype, genotype, and antimicrobial susceptibility.

Authors:  S Paju; P Carlson; H Jousimies-Somer; S Asikainen
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

Review 8.  Penicillin-binding proteins and bacterial resistance to beta-lactams.

Authors:  N H Georgopapadakou
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

9.  A novel in silico approach to identify potential therapeutic targets in human bacterial pathogens.

Authors:  Umashankar Vetrivel; Gurunathan Subramanian; Sudarsanam Dorairaj
Journal:  Hugo J       Date:  2011-04-08

10.  Modification in penicillin-binding proteins during in vivo development of genetic competence of Haemophilus influenzae is associated with a rapid change in the physiological state of cells.

Authors:  M Dargis; P Gourde; D Beauchamp; B Foiry; M Jacques; F Malouin
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.